Mirikizumab Benefit in UC Extends Into Maintenance Phase

(MedPage Today) -- The investigational monoclonal antibody mirikizumab was more effective in inducing and maintaining clinical remission in patients with moderate to severe ulcerative colitis (UC) compared with placebo, according to two phase III...
Source: MedPage Today Gastroenterology - Category: Gastroenterology Source Type: news